JIA YAO HLDGS(01626): Officially embarked on the business related to cannabis diol

JIA YAO HLDGS (01626) announced that the group has been focusing on the large health and biopharmaceutical industries in recent years. In April 2026, the group officially started conducting business related to cannabidiol (CBD). Currently, the group mainly engages in purchasing CBD from China and exporting to skincare, daily chemical, and pharmaceutical companies in Europe and North America. The group has established a dedicated operating team for this business, with core members having relevant industry experience. The group strictly adheres to relevant laws and regulations, conducting business on the basis of legality and compliance. As of the announcement date, the group has obtained the necessary qualifications and licenses for the business. In accordance with Chinese regulations, the group has obtained the "Record of Non-pharmaceutical Precursors Class I Chemicals," and for existing export business, the group has applied for and obtained the "Dual-Use Items and Technologies Export License," becoming one of the few Chinese companies legally engaged in CBD procurement and export business. Additionally, the group will closely monitor legal changes regarding CBD in various jurisdictions to ensure continued compliance. At present, the group mainly leverages its supply chain advantage to provide competitive prices for CBD to overseas markets. As of the announcement date, although the related business is in the early stages of development, substantial trade contracts have been signed, generating actual sales revenue and receipts. The group plans to gradually explore the feasibility of extending downstream end products (such as beauty and pet care) on the basis of deepening its existing European and Southeast Asian markets. The group will also continue to invest in research on related applications, including discussing product development cooperation with academic institutions. Furthermore, given that the medical application value of CBD has been confirmed by international authoritative medical journals and many countries and regions have relaxed policies on medical applications of CBD, the board of directors believes that market demand is expected to continue growing. The group's related business is expected to contribute positively to the company's future cash flow and profit growth.